9/14/2005

An FDA staff report says GlaxoSmithKline's Arranon appears to be effective against two rare types of blood cancer in cases where chemotherapy has not helped patients. An FDA advisory panel is scheduled to meet today to consider recommending approval of the drug.

Full Story:
Bloomberg

Related Summaries